Clinical trial NCT03125928: Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Official title: Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: HER2-positive Breast Cancer
Keywords: Atezolizumab
PD-L1
Lead sponsor: Fox Chase Cancer Center
Sponsor class: OTHER
Collaborators: name: Genentech, Inc.
First posted: 2017-04-24
Enrollment: 16
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single arm, Phase IIA clinical trial assessing the safety and efficacy of atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab in 50 patients with locally advanced, unresectable, or metastatic HER2-overexpressing breast cancer. Due to concerns that corticosteroids may have a negative effect on tumor immunity expected with addition of atezolizumab to the standard of care regimen, patients will receive premedication with dexamethasone only for weeks 1 and 2 of the weekly paclitaxel, and then corticosteroid premedication will be discontinued subsequently.

Patients must have pathologically confirmed HER2-overexpressing breast cancer that is locally recurrent, unresectable, or metastatic, with measurable disease as defined by RECIST v1.1. Tumor measurements and bone scans will be performed every 9 weeks while patients are on study.


Eligibility criteria: Inclusion Criteria:

* Women diagnosed with pathologically confirmed HER2-overexpressing breast cancer, that is locally recurrent, unresectable or metastatic (negative or positive for ER/PR, and positive for HER2).
* HER2 status confirmed positive by means of immunohistochemistry (IHC) or in situ hybridization (ISH) according to ASCO/CAP 2013 guidelines. It is considered positive if scored as 3+ by an IHC method defined as uniform membrane staining for HER2 in 10% or more of tumor cells or demonstrate HER2 gene amplification by an ISH method (single probe, average HER2 copy number ≥ 6.0 signals/cell; dual probe HER2/CEP17 ratio ≥2.0 with an average HER2 copy number ≥4.0 signals/cell; dual probe HER2/chromosome enumeration probe (CEP)17 ratio ≥2.0 with an average HER2 copy number \<4.0 signals/cell; HER2/CEP17 ratio \<2.0 with an average HER2 copy number ≥ 6.0 signals/cell).
* Have measurable clinical disease: Measurable disease, defined as at least 1 measurable lesion on a CT scan as defined by RECIST (version v1.1).
* Age \> 18 years.
* ECOG performance status 0,1or 2.
* Adequate organ function (defined by the following parameters): Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. Hemoglobin ≥ 10 g/dL.Platelets ≥ 100 x 109/L. Serum bilirubin ≤ 1.5 x upper normal limit (UNL), except patients with Gilbert's syndrome. Serum alanine aminotransferase (ALT) ≤ 2 x UNL or ≤ 5.0 x UNL in case of liver metastases. Serum aspartate aminotransferase (AST) ≤ 2 x UNL or ≤ 5.0 x UNL in case of liver metastases. Serum creatinine \< 140 μmol/L (\< 1.6 mg/dL) or 1.5x the upper limit of normal, whichever is less. Serum alkaline phosphatase (ALP) ≤ UNL or ≤ 2.5 x ULN in case of liver and bone metastases.
* Left ventricular ejection fraction of 50% or more at baseline (by echocardiography or multiple-gated acquisition scanning).
* Patients may have received one prior hormonal treatment for metastatic disease.
* Patients may have received adjuvant or neoadjuvant chemotherapy with or without trastuzumab and pertuzumab with an interval greater than than 12 months since completion of adjuvant/neoadjuvant treatment.
* Ability to understand and willingness to sign a written informed consent and HIPAA consent document.
* Female participants of childbearing age must be willing to use contraception methods, or abstain from sexual activity throughout the course of the study and for 7 months after the last dose of atezolizumab.
* Have provided tissue from a newly obtained biopsy obtained from a focus of metastatic disease, and be willing to consider repeat biopsy post-treatment after at least 4 cycles of treatment (an archival tissue sample may be substituted if new biopsy cannot be obtained and by discretion of Sponsor Investigator).

Exclusion Criteria:

* Patients participating in another trial of an investigational agent within 4 weeks of the 1st dose of the study.
* Patients with tumors that cannot be measured or clinically followed.
* Patients who had received therapy for metastatic breast cancer (other than that described above).
* Patients with active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 4 weeks prior to trial treatment.
* Patients with any baseline grade 2 neuropathy.
* Patients with known prior hypersensitivity reaction to any of the study drugs.
* Active autoimmune disease that is requiring systemic treatment within the past 3 months or documented history of clinically active autoimmune disease that requires systemic corticosteroids or immunosuppressive therapy.
* Diagnosis of immunosuppression or receiving steroid therapy or other immunosuppressive therapy within 4 weeks of the study.
* Have evidence of interstitial lung disease or active, non-infectious pneumonitis.
* Patients with human immunodeficiency virus (HIV1/2). An HIV test must be performed to confirm status prior to enrollment.
* Patients who are carriers of hepatitis virus B and C. Hepatitis B and C testing must be performed to confirm status prior to enrollment.
* Prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death 1 ligand (PDL-1), anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic T-lymphocyte -associated antigen-4 (CTLA-4) antibody.
* Pregnant, breastfeeding, or expecting to conceive within the projected time of the trial, starting with the pre-screening or screening visit and through 7 months after the last dose of trial treatment.
* Active infection requiring systemic therapy.
* Active substance abuse or psychiatric disorders.
* The use of a RANKL inhibitor (denosumab) must be discontinued during the study. Bisphosphonate therapy is permitted.
* The following treatments must be discontinued: Herbal Medications. Immunomodulatory agents, including but not limited to interferons or IL-2. Immunosuppressive medications, including but not limited to cyclophosphamide, azathioprine, methotrexate, and thalidomide. Systemic corticosteroids. Anti-TNF-α agents.
* Any live, attenuated vaccine within 28 days prior to the first day of treatment or during study treatment, or unwillingness to avoid live, attenuated vaccines within 90 days following the last dose of atezolizumab.

Primary outcomes:
measure: Number of participants with treatment-related adverse events
timeFrame: Up to 5 years after stopping study treatment
measure: Antitumor activity of atezolizumab plus the standard regimen of paclitaxel, trastuzumab, and pertuzumab
timeFrame: An average of 18 weeks
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: Up to 5 years after the last patient stops treatment
measure: Time to tumor progression (TTP)
timeFrame: Up to 5 years after the last patient stops treatment
measure: Time to treatment failure (TTF)
timeFrame: Up to 5 years after the last patient stops treatment
measure: Progression free survival (PFS)
timeFrame: Up to 5 years after the last patient stops treatment
measure: Clinical benefit rate (CBR)
timeFrame: Up to 5 years after the last patient stops treatment
measure: Duration of response (DOR)
timeFrame: Up to 5 years after the last patient stops treatment
measure: Correlation of biomarkers related to PD-L1 blockade with objective response rate (ORR), CBR, PFS, OS, and DOR.
timeFrame: Up to 5 years after the last patient stops treatment
measure: Efficacy according to hormone receptor status (ER/PR)
timeFrame: Up to 5 years after the last patient stops treatment
measure: Feasibility of discontinuation of corticosteroids use after 2 weekly doses of paclitaxel
timeFrame: Up to 5 years after the last patient stops treatment
measure: Rate of occurrence of paclitaxel-related infusion hypersensitivity reaction after discontinuation of corticosteroids
timeFrame: An average of 18 weeks
measure: Cardiac safety
timeFrame: An average of 18 weeks
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
Study officials:
References: